I started writing an article on $KVUE -- the consumer health company spun off from $JNJ -- and saw that it took $AAP's spot in the S&P 500 Index in late August.

This makes sense as it is a $40B+ market capitalization home to some of America's most recognizable brands.

However, it began trading on its own back in May. So now I'm curious.

Once it officially separated from Johnson & Johnson in May, were the S&P 500 tracking ETFs and mutual funds that held J&J -- and received shares of KVUE from the spinoff -- forced to sell their new Kenvue shares in May and now repurchase them in August and September?

Or do they have some leeway in anticipating that it will probably be added back to the S&P 500 later?

It's not a wildly important question, but I'm just thinking out loud.

Generally, stocks receive a boost once it is announced they are joining the S&P 500 -- see $ABNB and $BX -- but Kenvue has just steadily slid down nearly 20% since it started trading.

I'm curious to see if anyone here may know the logistics of these movements or have an idea of how things may turn out.

I recently touched base on three of my favorite growth stocks that have been sold off a bit over the last month in $FTNT, $DOCN, and $GLBE.

Here is my ongoing thesis on each:

I would love to hear which business you all like the most or if you have any worries about my thesis for any of these stocks.

Thank you for reading 🙏

With $SOFI up 88% and $KNSL up 41% year to date, the two financial stocks are now my largest holdings.

Whereas I have stopped adding to some core holdings like $NVDA and $UPST that have risen quickly, I still think SoFi and Kinsale are interesting at today's prices.

So who is the better buy?

Here's my favorite thing about each company at the moment:

All in all, I really like both, but Kinsale's growth may be "safer" thanks to its stellar profitability.

I would love to hear what you all think about these two businesses -- thanks for reading. 🙏

I wanted to think aloud with you all regarding my core portfolio changes coming up at year's end.

Each year I add one new stock to my "core portfolio" to keep the ratio of stocks in my core portfolio the same as my age -- 35.

The purpose of these 35 core holdings is to group my favorite current stocks together, making them easy to add to with dollar-cost averaging.

I also allow myself the opportunity to turn over 10% of that core portfolio, meaning I'll switch four stocks out for new ones next year.

However, while these stocks will be removed as core holdings, they will not be sold -- just not actively added to like the rest of the portfolio.

For example, I dropped $SE, $TWLO, and $DOCU last year and added $V/$MA (split), $PGNY, $POOL, and $TREX.

Here was the portfolio before that change:

This year, I have decided that $TDOC and $RBLX are out the door already, with $PINS, $U, $UPST, $ROKU, and $FDX potentially on the chopping block.

Conversely, I am almost sure to add $DOCS and $ODFL to replace Teladoc and Roblox.

That leaves two more stocks to drop and three more to add.

Here's a list of my other candidates to add with a few words on why they're interesting:

Of course, this is an incomplete watchlist, but I wanted to put it in writing all the same.

I would love to hear what you would choose from these or if you have a stock that may be a better idea.

Thanks as always for reading. 🙏

I recently revisited four of my favorite healthcare-related stocks in $DOCS, $PGNY, $MEDP, and $INMD and discussed why they all look like interesting buys for the long term.

Here's my investment thesis on each:

Would love to hear your thoughts on these four, or which one is your favorite.

Thanks as always for reading. 🙏

I recently wrote about one of my favorite picks at this moment in time -- $POOL -- and why I will keep adding to it through July.

Currently, the company is a core holding for my daughter and myself, which is the only stock where that is the case so far.

Aside from its leadership position and past outperformance, there are three specific reasons why history may suggest Pool is set to beat the market over the long term if we buy today.

1) Its Return on Invested Capital (ROIC) of 25% is good for the top quintile among its S&P 500 peers. Generally, stocks in the top quintile of ROIC rankings tend to outperform. Specifically, from 2003 to 2020, the top quintile of ROICs in Motley Fool's investable universe nearly doubled the returns of their lower-ranked peers, making Pool's figures intriguing.

2) Pool's 1.2% dividend has grown by 20% annually over the last decade and has been raised for 12 straight years. Better yet, however, its payout ratio has declined from 35% to 23%, highlighting its rapid earnings growth and pointing to future dividend increase potential. With dividend growth stocks in the S&P 500 beating the broader index by 2.5% annually since 1973, Pool again looks promising.

3) Trading at just 22 times earnings, Pool's P/E ratio in 2023 has been the lowest it has been compared to any point across the last decade -- where it averaged 30. While it will take time for the pool industry to recover from its currently weak macroeconomic environment, today's price looks great for investors looking decades ahead.

Thanks to these three historical indicators -- and the fact the Pool generates 83% of its sales from non (or somewhat) discretionary sales like maintenance, repairs, remodeling, and reonvations -- Pool is my favorite buy for July.

Would love to hear what you all think of this pick for the long haul.

Thanks as always for reading. 🙏

I watched a beautifully simple Half as Interesting video explaining how quantum tunneling will put a theoretical end to Moore's Law.

While I'm not smart enough to know if Moore's Law enabled ASML's run or if ASML's lithography enabled Moore's Law, it seems that the law's exponential growth is due to end -- a topic the Financial Times tackled in this informational article:

I'll fully admit to this being far outside of my wheelhouse -- and I'm saying by no means that ASML is in imminent danger (it is still a core holding for me) -- but I am curious what type of reimagining will be needed by the company, looking 10-20-30 years ahead.

I would be curious to hear your best ideas of where ASML, or this space in general, may be headed -- or if the market's current vote for $NVDA to take charge is the most likely winner over the long haul.

One of my favorite "stocked ponds" to fish in for new investments are somewhat recent IPOs that have now been trading on the markets for over a year or two.

This little bit of time gives us at least four earnings reports, one 10-k, and the opportunity for standard IPO hype to wear off.

One company currently fitting this billing is Doximity $DOCS, which I rambled a bit about here:

After briefly trading above $100 shortly after its IPO, the company has settled in around the low $30s today and looks rather interesting, in my opinion.

Here is a brief synopsis of what makes Doximity worth a look:

Ultimately, Doximity isn't cheap, but its 17x and 11x ad spend ROI for health systems and pharma customers should keep advertisers coming back.

Growing revenue by 22% in a year that saw most ad-dependant businesses struggle to some extent is just fine by me.

Looking a decade out, Doximity's $6B market cap doesn't seem to match the company's potential, thanks to its ability to get advertisers directly in front of the eyes of its highly engaged physicians.

Early last week, once it was clear that $FRC was heading out of the S&P 500, I started thinking out loud about who may be the next addition.

I (selfishly) settled on four I liked: $AXON, $TTD, $VEEV, and $ABNB, and started researching for an article.

However, before I got there, the index added Axon. And before I get yeah right'd directly out of the room, it's all on Twitter if it's important to you at all. 😂

So I shifted and wrote this article on why I still like Trade Desk, Veeva, and Airbnb to go next.

Here's some reasoning for why each would be interesting for the S&P Index, as all three seem to meet the necessary market cap and profitability requirements.

Curious to know what you all think of these picks -- or who you might add instead.

Thanks as always for reading. 🙏

I was reading through an $ABNB transcript from a Morgan Stanley Technology conference in March, and this portion jumped right off the page.

It is a bit lengthy but well worth the read as it seems like a fascinating insight into Brian Chesky's (co-founder and CEO) mind and kind of hit home.

And I said, I don't know, is it cardiac? Is it like obesity? Is it cancer? Is it cardiac disease?

And he said, no, it's loneliness. Loneliness takes 15 years off your life. And I thought, wow, that's pretty bad, but how prevalent is this?

Well, I'm not saying we're here to solve this problem. No one company is.

I know he's talking his book a little bit, of course, in some of this, but it does provide a layer of happiness to me as a shareholder to see this thinking flowing through the company's operations.

Curious to know what you all may think.